LB1777: A Novel Ex Vivo Model of Human Hair Follicle Immune Privilege Collapse Reveals the Potential of Farudodstat, a DHODH Inhibitor, as a Therapeutic for Alopecia Areata Treatment

This study explores the potential of farudodstat, a DHODH inhibitor, as a treatment for alopecia areata (AA), an inflammatory disorder characterized by immune privilege (IP) collapse and hair loss. Using an innovative ex vivo model with human hair follicles (HFs), researchers stimulated T-cell activation to mimic AA conditions. The study found that farudodstat significantly reduced T-cell proliferation and MHC protein expression, indicating a protective effect against IP collapse without promoting catagen induction or affecting keratinocyte proliferation. These findings suggest that farudodstat could be a promising therapeutic option for AA by preventing IP collapse.